Clinical Trial Update: Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating neoadjuvant chemotherapy and hypofractionated radiotherapy combined with the PD-1 antibody tisle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING